trimipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 2758 739-71-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trimipramine
  • rhotrimine
  • trimeprimine
  • trimeproprimine
  • trimipramine maleate
  • surmontil
  • trimipramine maleate salt
  • trimipramine mesylate
  • trimipramine monohydrochloride
Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.
  • Molecular weight: 294.44
  • Formula: C20H26N2
  • CLOGP: 5.44
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.05
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O
0.15 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.31 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 23 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 12, 1979 FDA ODYSSEY PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Deafness transitory 101.57 23.16 23 3298 1947 63483754
Functional gastrointestinal disorder 83.95 23.16 23 3298 4236 63481465
Coma 77.92 23.16 46 3275 64318 63421383
Abnormal loss of weight 77.00 23.16 23 3298 5759 63479942
Traumatic coma 76.80 23.16 11 3310 61 63485640
Gastrointestinal pain 65.13 23.16 23 3298 9753 63475948
Feeding disorder 58.13 23.16 23 3298 13339 63472362
Pneumonia aspiration 47.92 23.16 27 3294 34513 63451188
Suicide attempt 47.46 23.16 33 3288 60885 63424816
Eating disorder 47.18 23.16 22 3299 18994 63466707
Toxicity to various agents 46.90 23.16 61 3260 247189 63238512
Pharyngitis 45.97 23.16 22 3299 20121 63465580
Musculoskeletal disorder 45.46 23.16 22 3299 20622 63465079
Parachute mitral valve 43.13 23.16 7 3314 97 63485604
Atrial septal defect 41.22 23.16 15 3306 6923 63478778
Hypophagia 39.51 23.16 23 3298 31236 63454465
Coarctation of the aorta 36.65 23.16 8 3313 571 63485130
Ear infection 35.25 23.16 23 3298 38190 63447511
Drug abuse 33.88 23.16 29 3292 72489 63413212
Polyglandular autoimmune syndrome type II 32.69 23.16 5 3316 46 63485655
Gastrooesophageal reflux disease 32.50 23.16 32 3289 95607 63390094
Patent ductus arteriosus 32.16 23.16 11 3310 4239 63481462
Victim of sexual abuse 29.98 23.16 7 3314 677 63485024
Product prescribing error 29.71 23.16 18 3303 26271 63459430
Miosis 29.69 23.16 12 3309 7341 63478360
Underdose 28.99 23.16 18 3303 27438 63458263
Ventricular septal defect 28.01 23.16 10 3311 4368 63481333
Drug interaction 26.68 23.16 45 3276 229086 63256615
Incorrect dosage administered 26.56 23.16 8 3313 2055 63483646
Somnolence 26.19 23.16 39 3282 178646 63307055
Prescription drug used without a prescription 25.42 23.16 8 3313 2378 63483323

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prescription drug used without a prescription 108.39 31.34 23 1226 2131 34953551
Drug interaction 75.75 31.34 63 1186 225883 34729799
Brain oedema 73.85 31.34 25 1224 13796 34941886
Toxicity to various agents 61.12 31.34 53 1196 200309 34755373
Pulmonary oedema 46.88 31.34 26 1223 47503 34908179

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prescription drug used without a prescription 121.08 22.34 30 3816 4055 79736487
Toxicity to various agents 95.40 22.34 109 3737 421431 79319111
Drug interaction 91.65 22.34 106 3740 415077 79325465
Coma 91.10 22.34 58 3788 100591 79639951
Traumatic coma 71.49 22.34 10 3836 50 79740492
Brain oedema 64.24 22.34 29 3817 25234 79715308
Pneumonia aspiration 44.72 22.34 32 3814 66935 79673607
Drug abuse 39.88 22.34 44 3802 162647 79577895
Suicide attempt 38.65 22.34 32 3814 82900 79657642
Deafness transitory 38.17 22.34 9 3837 986 79739556
Somnolence 38.09 22.34 52 3794 238929 79501613
Gastrooesophageal reflux disease 34.22 22.34 33 3813 104213 79636329
Miosis 33.51 22.34 16 3830 15773 79724769
Victim of sexual abuse 32.29 22.34 7 3839 525 79740017
Underdose 29.67 22.34 19 3827 33132 79707410
Incorrect dosage administered 24.80 22.34 8 3838 2791 79737751
Loss of consciousness 24.42 22.34 35 3811 167908 79572634
Functional gastrointestinal disorder 23.85 22.34 9 3837 4981 79735561
Eyelid bleeding 23.83 22.34 4 3842 75 79740467
Pulmonary oedema 23.57 22.34 25 3821 88229 79652313
Abdominal pain lower 23.09 22.34 16 3830 31766 79708776
Product prescribing error 22.35 22.34 18 3828 44795 79695747

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA06 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
FDA EPC N0000175752 Tricyclic Antidepressant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Neuralgia off-label use 16269008
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Electroconvulsive therapy contraindication 23835007
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Schizophrenia contraindication 58214004 DOID:5419
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 5.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.83 PDSP IUPHAR
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 5.61 IUPHAR CHEMBL
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 5.42 PDSP IUPHAR
Histamine H1 receptor GPCR ANTAGONIST Ki 8.85 PDSP
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 4.96 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.56 CHEMBL

External reference:

IDSource
4019962 VUID
N0000148047 NUI
D00394 KEGG_DRUG
521-78-8 SECONDARY_CAS_RN
4018060 VANDF
4019962 VANDF
C0041056 UMLSCUI
CHEBI:9738 CHEBI
CHEMBL644 ChEMBL_ID
DB00726 DRUGBANK_ID
CHEMBL1200948 ChEMBL_ID
D014299 MESH_DESCRIPTOR_UI
5584 PUBCHEM_CID
7317 IUPHAR_LIGAND_ID
1414 INN_ID
25332-13-2 SECONDARY_CAS_RN
6S082C9NDT UNII
10834 RXNORM
2164 MMSL
5636 MMSL
72541 MMSL
d00873 MMSL
001507 NDDF
004605 NDDF
005363 NDDF
373550009 SNOMEDCT_US
734496007 SNOMEDCT_US
87831009 SNOMEDCT_US
90426002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 42806-802 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 42806-803 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 42806-804 CAPSULE 100 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-944 CAPSULE 25 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-944 CAPSULE 25 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-945 CAPSULE 50 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-945 CAPSULE 50 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-946 CAPSULE 100 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-946 CAPSULE 100 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 64850-850 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 64850-851 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 64850-852 CAPSULE 100 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68462-804 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68462-805 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68462-806 CAPSULE 100 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2061 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2062 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2063 CAPSULE 100 mg ORAL ANDA 22 sections